Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.

The Journal of antimicrobial chemotherapy - 1 Oct 2007

Cleijsen R M M, van de Ende M E, Kroon F P, Lunel F Verduyn, Koopmans P P, Gras L, de Wolf F, Burger D M

Abstract excerpt

BACKGROUND: Therapeutic drug monitoring (TDM) is being applied for a number of antiretroviral agents. Little is known about the use of TDM for atazanavir. METHODS: This is a retrospective cohort analysis on the use of TDM of atazanavir at three clinical sites in The Netherlands. Patients were divided into three groups: (i) all patients with evaluable data of plasma atazanavir concentrations and its relationship...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bilirubin
Share to Drug Monitoring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Netherlands

Share to Oligopeptides

Share to Plasma

Share to Pyridines

Source

Identifiers

PMID: 17704117
DOI: 10.1093/jac/dkm298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.PMID 17704117Read ↗

The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients.Semantic proximity Read ↗

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Semantic proximity Read ↗

Negligible effect of tenofovir on atazanavir trough concentrations and genotypic inhibitory quotients in the presence and absence of ritonavir.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.Semantic proximity Read ↗

Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.Semantic proximity Read ↗

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Semantic proximity Read ↗

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).Semantic proximity Read ↗

Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.Semantic proximity Read ↗

Therapeutic drug monitoring in highly active antiretroviral therapy.Semantic proximity Read ↗

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.Semantic proximity Read ↗

Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.Semantic proximity Read ↗

[Viral resistance and genetic barrier of atazanavir].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.